{"slideshow_credits": null, "snippet": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Leslie", "role": "reported", "lastname": "PICKER", "rank": 1, "organization": ""}], "original": "By LESLIE PICKER"}, "web_url": "http://www.nytimes.com/2016/02/04/business/dealbook/editas-medicine-and-beigene-gain-in-market-debuts.html", "lead_paragraph": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "headline": {"main": "Editas Medicine and BeiGene Gain in Market Debuts"}, "_id": "56b23fb338f0d82036f0a7aa", "word_count": "379", "multimedia": [], "pub_date": "2016-02-04T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Initial Public Offerings", "is_major": "N", "rank": "1"}, {"name": "organizations", "value": "Beigene Ltd.", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "Editas Medicine Inc", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Genetics and Heredity", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}